Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1636 1637 1653 1682 1699 4100
This examiner grants 51% of resolved cases
Jenna L Persons works in Art Unit 1636 of Tech Center 4100. The examiner has 63 resolved cases and an allowance rate of 50.8 percent. This indicates a balanced outcome for applications in this unit. The examiner's record provides an initial look at prosecution history in this unit.
The interview lift is 61.7 percent, indicating that interviews significantly increase the probability of allowance compared to the overall rate of 50.8 percent. This is a highly recommended strategy for practitioners. The median time to allowance for successful applications is 1317 days. This pendency helps applicants estimate the time required to reach a final decision.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18035901 | METHODS AND MATERIALS FOR TREATING HEART FAILURE | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17785070 | PROGRAMMABLE DNA NUCLEASE-ASSOCIATED LIGASE AND METHODS OF USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 16772222 | CAS12B SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED DNA BASE EDITING | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18535052 | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18469344 | SERPINA-MODULATING COMPOSITIONS AND METHODS | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17815849 | METHOD OF TREATING HER2-POSITIVE BREAST CANCER | Final Rejection | University of Cincinnati |
| 18549252 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING T CELL DYSFUNCTION | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17786147 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17599023 | METHODS FOR TREATING CANCERS USING ANTISENSE | Final Rejection | Thomas Jefferson University |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17428322 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | Non-Final OA | BIONTECH SE |
| 18286880 | PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF | Non-Final OA | Nanjing GenScript Biotech Co., Ltd. |
| 17284232 | METHODS AND COMPOSITIONS FOR EDITING RNAS | Final Rejection | EDIGENE THERAPEUTICS (BEIJING) INC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy